weight loss semaglutide vs tirzepatide for Semaglutide vs Tirzepatide: Which GLP-1

Q1 2025: Eli Lilly acquires Synthekine for $1.2 billion to expand GLP-1 and metabolic disease pipeline Eli Lilly announced the acquisition of Synthekine, a biotech specializing in cytokine therapeutics, to enhance its pipeline of GLP-1 and related metabolic disease treatments

Looking ahead, Al-Aly said, the findings support the case for clinical trials to test GLP-1 medications as treatments for addiction in their own right, including trials powered to measure effects on overdose and drug-related death

Claim 34: not more than a 22% risk experiencing a Previously Presented event of nausea/vomiting/diarrhea on a weekly basis

A multidimensional strategy would enhance both diagnostic and prognostic capabilities, offering a more integrative view of neurodegenerative pathophysiology